In Vitro HIV-1 Evolution in Response to Triple Reverse Transcriptase Inhibitors & In Silico Phenotypic Analysis

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Rath, Barbara A ^a,c   Yousef, Kaveh Pouran ^b   Katzenstein, David K ^c   Shafer, Robert W ^c   Schütte, Christof ^b   von Kleist, Max ^b   Merigan, Thomas C ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ARTICLE; EVOLUTION; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHENOTYPE; VIRAL GENETICS; VIROGENESIS;

AMINO ACID SUBSTITUTION; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; GENETIC FITNESS; HIV-1; HUMANS; KINETICS; MUTATION; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; SERIAL PASSAGE; STOCHASTIC PROCESSES; TIME FACTORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84876206921     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061102     Document Type: Article

References (63)

1. Martinez-Cajas JL, Wainberg MA, (2008) Antiretroviral therapy: optimal sequencing of therapy to avoid resistance. Drugs 68: 43-72.
2. Reekie J, Mocroft A, Ledergerber B, Beniowski M, Clotet B, et al. (2010) History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change. HIV Med 11: 469-478.
3. Chou R, Fu R, Huffman LH, Korthuis PT, (2006) Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses. Lancet 368: 1503-1515.
4. Esnouf R, Ren J, Ross C, Jones Y, Stammers D, et al. (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol 2: 303-308.
5. Spence RA, Kati WM, Anderson KS, Johnson KA, (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science (New York, N Y) 267: 988-993.
6. Frank M, von Kleist M, Kunz A, Harms G, Schutte C, et al. (2011) Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes. Antimicrob Agents Chemother 55: 5529-5540.
7. von Kleist M, Metzner P, Marquet R, Schutte C, (2012) HIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selection. PLoS Comput Biol 8: e1002359.
8. Fisher EJ, Chaloner K, Cohn DL, Grant LB, Alston B, et al. (2001) The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS 15: 1695-1700.
9. DHHS (2012) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents Available: http://wwwaidsinfonihgov/ContentFiles/AdultandAdolescentGLpdf.1-239. PP. Accessed 2012 Apr 26.
10. Sierra-Aragon S, Walter H, (2012) Targets for inhibition of HIV replication: entry, enzyme action, release and maturation. Intervirology 55: 84-97.
11. Herman BD, Votruba I, Holy A, Sluis-Cremer N, Balzarini J, (2010) The acyclic 2,4-diaminopyrimidine nucleoside phosphonate acts as a purine mimetic in HIV-1 reverse transcriptase DNA polymerization. J Biol Chem 285: 12101-12108.
12. Sluis-Cremer N, Sheen CW, Zelina S, Torres PS, Parikh UM, et al. (2007) Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 51: 48-53.
13. Weinreich DM, Watson RA, Chao L, (2005) Perspective: Sign epistasis and genetic constraint on evolutionary trajectories. Evolution 59: 1165-1174.
14. Breen MS, Kemena C, Vlasov PK, Notredame C, Kondrashov FA, (2012) Epistasis as the primary factor in molecular evolution. Nature 490: 535-538.
15. von Kleist M, Menz S, Stocker H, Arasteh K, Schutte C, et al. (2011) HIV quasispecies dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirs. PLoS One 6: e18204.
16. Gianotti N, Tiberi S, Menzo S, Danise A, Boeri E, et al. (2008) HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy. J Med Virol 80: 201-208.
17. Buckheit RW Jr, (2004) Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy. Expert Opin Investig Drugs 13: 933-958.
18. Castagna A, Danise A, Menzo S, Galli L, Gianotti N, et al. (2006) Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS 20: 795-803.
19. Rath B, Olshen RA, Halpern J, Merigan TC, (2012) Persistence versus Reversion of 3 TC Resistance in HIV-1 Determine the Rate of Emergence of NVP Resistance. Viruses 4: 1212-1234.
20. Melikian GL, Rhee SY, Taylor J, Fessel WJ, Kaufman D, et al. (2012) Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility. Antimicrob Agents Chemother 56: 2305-2313.
21. Palmer S, Shafer RW, Merigan TC, (1999) Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS 13: 661-667.
22. Tang MW, Shafer RW, (2012) HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs 72: e1-25.
23. Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, et al. (1990) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250: 1411-1413.
24. Winters MA, Schapiro JM, Lawrence J, Merigan TC, (1998) Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. J Virol 72: 5303-5306.
25. Nijhuis M, Boucher CA, Schuurman R (1995) Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction. Biotechniques 19: 178-180, 182.
26. Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, et al. (1996) The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 124: 1039-1050.
27. Winters MA, Coolley KL, Girard YA, Levee DJ, Hamdan H, et al. (1998) A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 102: 1769-1775.
28. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, et al. (2003) Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 31: 298-303.
29. Allen LJS (2011) An introduction to stochastic processes with applications to biology. Boca Raton, FL: Chapman & Hall/CRC. xxiv, 466 p. p.
30. Perelson AS, Nelson PW, (1999) Mathematical analysis of HIV-1 dynamics in vivo. Siam Review 41: 3-44.
31. von Kleist M, Menz S, Huisinga W, (2010) Drug-class specific impact of antivirals on the reproductive capacity of HIV. PLoS Comput Biol 6: e1000720.
32. Bonate PL (2006) Pharmacokinetic-Pharmacodynamic Modeling and Simulation. New York, NY: Springer.
33. Norris JR (1998) Markov chains. Cambridge, UK; New York: Cambridge University Press. xvi, 237 p. p.
34. Gardiner CW (2004) Handbook of stochastic methods for physics, chemistry, and the natural sciences. Berlin; New York: Springer-Verlag. xvii, 415 p. p.
35. Engblom S, (2006) Computing the moments of high dimensional solutions of the master equation. Applied Mathematics and Computation 180: 498-515.
36. Gillespie DT (1992) Markov processes: an introduction for physical scientists. San Diego: Academic Press.
37. Hogg RV, McKean JW, Craig AT (2013) Introduction to mathematical statistics. Boston: Pearson. x, 694 p.
38. Goon A (1962) Fundamentals of statistics. Calcutta,: World Press. 401 p.
39. Bonate PL (2011) Pharmacokinetic-pharmacodynamic modeling and simulation. New York: Springer.
40. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, et al. (2011) 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 19: 156-164.
41. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, et al. (2009) Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 4: e4724.
42. Shulman N, Zolopa AR, Passaro D, Shafer RW, Huang W, et al. (2001) Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS (London, England) 15: 1125-1132.
43. Shulman NS, Bosch RJ, Mellors JW, Albrecht MA, Katzenstein DA, (2004) Genetic correlates of efavirenz hypersusceptibility. AIDS (London, England) 18: 1781-1785.
44. Katzenstein DA, Bosch RJ, Hellmann N, Wang N, Bacheler L, et al. (2003) Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs. AIDS (London, England) 17: 821-830.
45. Bosch RJ, Downey GF, Katzenstein DA, Hellmann N, Bacheler L, et al. (2003) Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenz. AIDS (London, England) 17: 2395-2396.
46. Martinez-Picado J, Morales-Lopetegi K, Wrin T, Prado JG, Frost SD, et al. (2002) Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS 16: 895-899.
47. Bonhoeffer S, Chappey C, Parkin NT, Whitcomb JM, Petropoulos CJ, (2004) Evidence for positive epistasis in HIV-1. Science (New York, N Y) 306: 1547-1550.
48. Martinez JP, Bocharov G, Ignatovich A, Reiter J, Dittmar MT, et al. (2011) Fitness ranking of individual mutants drives patterns of epistatic interactions in HIV-1. PLoS One 6: e18375.
49. Ren J, Stammers DK, (2008) Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. Virus Res 134: 157-170.
50. Gatanaga H, Ode H, Hachiya A, Hayashida T, Sato H, et al. (2010) Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine. Antimicrob Agents Chemother 54: 1596-1602.
51. Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, et al. (2001) Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 75: 4999-5008.
52. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, et al. (2000) A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 44: 920-928.
53. Cong ME, Heneine W, Garcia-Lerma JG, (2007) The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol 81: 3037-3041.
54. Sharma PL, Nurpeisov V, Hernandez-Santiago B, Beltran T, Schinazi RF, (2004) Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Curr Top Med Chem 4: 895-919.
55. Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, et al. (2005) Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis 41: 236-242.
56. Goudsmit J, de Ronde A, de Rooij E, de Boer R, (1997) Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J Virol 71: 4479-4484.
57. Yerly S, Rakik A, De Loes SK, Hirschel B, Descamps D, et al. (1998) Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J Virol 72: 3520-3523.
58. de Ronde A, van Dooren M, van Der Hoek L, Bouwhuis D, de Rooij E, et al. (2001) Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol 75: 595-602.
59. Kepler TB, Perelson AS, (1998) Drug concentration heterogeneity facilitates the evolution of drug resistance. Proc Natl Acad Sci U S A 95: 11514-11519.
60. Arora P, Dixit NM, (2009) Timing the emergence of resistance to anti-HIV drugs with large genetic barriers. PLoS Comput Biol 5: e1000305.
61. Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentre F, et al. (2010) Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action. Clinical pharmacokinetics 49: 17-45.
62. Cohen J, (2011) HIV/AIDS research. Tissue says blood is misleading, confusing HIV cure efforts. Science (New York, N Y) 334: 1614.
63. North TW, Higgins J, Deere JD, Hayes TL, Villalobos A, et al. (2010) Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. Journal of virology 84: 2913-2922.